多巴胺和葡萄提取物装载的固体脂质纳米粒子:粒子与分化SH-SY5Y神经细胞模型帕金森病之间的相互作用研究
Rosanna Mallamaci1, Debora Musarò2, Marco Greco2
1Department of Biosciences, Biotechnologies and Environment, University of Bari "Aldo Moro", 70125 Bari, Italy.
Molecules (Basel, Switzerland)
|April 27, 2024
概括
这项研究探讨了固体脂质纳米颗粒 (SLN) 以提供多巴胺和葡萄提取物来对抗帕金森病 (PD) 神经退行. 新的SLN配方显示出细胞保护作用和通过血脑屏障 (BBB) 增强药物输送的潜力.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物技术是生物技术.
背景情况:
- 帕金森病 (PD) 涉及多巴胺神经元损失,目前的治疗受到血脑屏障 (BBB) 的阻碍.
- 在BBB中有效的药物输送仍然是PD治疗的重大挑战.
研究的目的:
- 为了研究多巴胺 (DA) 和葡萄提取物 (GSE) 的同时使用固体脂质纳米粒子 (SLN) 治疗PD.
- 在体外评估DA/GSE载入SLN的细胞相容性,对Rotenone的细胞保护以及抗氧化作用.
- 在神经毒性模型中评估SLN在调节α-synuclein (aS) 水平方面的潜力.
主要方法:
- 两种SLN配方的合成:DA-co-GSE-SLNs和GSE-ads-DA-SLNs. 这两种配方的合成.
- 用颗粒大小,泽塔潜力和药物封装效率来表征SLN.
- 在体外评估使用差异化SH-SY5Y细胞来评估细胞相容性,氨酸诱导的毒性,氧化应激和aS水平.
主要成果:
- SLN配方的颗粒大小在187-297nm之间,泽塔电位为-4.1至-9.7mV.
- 根据SLN的配方,DA关联效率从35%到82%不等.
- DA/GSE-SLNs表现出细胞相容性,显著的细胞保护作用,对Rotenone,和调节的Rotenone诱导的aS水平的增加.
结论:
- SLN显示承诺作为一个可行的交付系统,用于联合管理多巴胺和抗氧化剂,用于帕金森病.
- 这些SLN配方为克服BBB挑战和增强神经退行性疾病治疗效果提供了潜在的策略.
- 该研究强调了SLN在缓解神经毒性和调节PD模型中关键病理标志物的潜力.
相关概念视频
Parkinson's Disease: Treatment
264
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
264
Parkinson's Disease: Overview
537
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
537


